Clinical Research Directory

Inclusion Criteria: * Newly diagnosed GBM confirmed by post-op pathology/biopsy, MGMT promoter methylation positive, no prior RT or chemo. * Surgery/biopsy ≤ 21 days before enrollment. * Age 18-75 years any gender. * KPS ≥ 70. * Organ function (no blood components or growth factors within 14 days): 1. ANC ≥ 1.5 × 10⁹/L; PLT ≥ 100 × 10⁹/L; Hb ≥ 90 g/L. 2. Total bilirubin ≤ 1.5 × ULN. 3. ALT, AST ≤ 3 × ULN. 4. Serum creatinine ≤ 1.5 × ULN or CrCl ≥ 50 mL/min. * Life expectancy ≥ 12 weeks. * Stable or tapering corticosteroid dose for 14 days. * Voluntary participation, signed informed consent, and good compliance. Exclusion Criteria: * Allergy to Lenvatinib, TMZ, or components. * Other malignancies within 5 years or concurrent, or prior anti-tumor therapy. * Concurrent participation in another clinical trial (except observational). * Comorbidities interfering with treatment: 1. Grade 4 non-hematological toxicity (except hair loss, nausea, vomiting). 2. Conditions interfering with oral drugs (dysphagia, chronic diarrhea, bowel obstruction). * Evidence of increased intracranial pressure (midline shift \> 5 mm, papilledema, vomiting, decreased consciousness). * History of drug/alcohol abuse. * Pregnancy or lactation. * Other conditions judged by the investigator (e.g., unstable heart/kidney disease, uncontrolled diabetes, mood disorders).